---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-25-028188"
form_type: "8-K"
ticker: "IKT"
cik: "0001750149"
company_name: "Inhibikase Therapeutics, Inc."
filed_at: "2025-02-18T23:59:59+00:00"
generated_at: "2026-05-26T17:04:26.887509+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Inhibikase appoints Mark Iwicki as CEO; founder Milton Werner resigns

## Summary
- Milton Werner resigned as CEO/board member effective Feb 13, 2025; will consult through May 13, 2025 at $44,583/month.
- Mark Iwicki appointed CEO, President and director effective Feb 14, 2025; base salary $710K, bonus up to 60%, options for 15.1M shares.
- Amit Munshi named independent Chair of the Board, replacing Roberto Bellini who remains a director.
- Company advancing IkT-001Pro in Phase 2b trial with $110M from October financing; new CEO has PAH expertise.

## SEC filing metadata
- accession: 0001193125-25-028188
- form_type: 8-K
- ticker: IKT
- cik: 0001750149
- company_name: Inhibikase Therapeutics, Inc.
- filed_at: 2025-02-18T23:59:59+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 5.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1750149/000119312525028188/0001193125-25-028188-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1750149/000119312525028188/d835160d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-25-028188
- JSON: https://secwatch.observer/filing/0001193125-25-028188.json
- Plain text: https://secwatch.observer/filing/0001193125-25-028188.txt

## Key facts
- Executive change
  Milton H. Werner resigned as Chief Executive Officer at Inhibikase Therapeutics, Inc..
  - Action: resigned
  - Role: Chief Executive Officer
  source text: Effective February 13, 2025, Milton H. Werner, Ph.D. resigned as President, Chief Executive Officer and principal executive officer of Inhibikase Therapeutics, Inc. (the “Company”) and as a member of the Board of Directors (the “Board”) of the Company (the “Resignation”).
  evidence_url: https://www.sec.gov/Archives/edgar/data/1750149/000119312525028188/0001193125-25-028188-index.htm
- Executive change
  Mark Iwicki was appointed as Chief Executive Officer at Inhibikase Therapeutics, Inc..
  - Action: appointed
  - Role: Chief Executive Officer
  source text: Effective February 14, 2025, the Board appointed Mark Iwicki as President, Chief Executive Officer and principal executive officer of the Company (the “Appointment”).
  evidence_url: https://www.sec.gov/Archives/edgar/data/1750149/000119312525028188/0001193125-25-028188-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.